Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 7Other solid neoplasm 1

Conditions

Advanced Solid Tumors 481Solid Tumor 418Advanced Solid Tumor 409Unspecified Adult Solid Tumor, Protocol Specific 350Solid Tumors 322Mesothelioma, Malignant 281Mesothelioma 244Solid Tumor, Adult 113Carcinoma, Non-Small-Cell Lung 109Retinoblastoma 81Ovarian Neoplasms 65Lung Neoplasms 61Melanoma 56Sarcoma 52Stomach Neoplasms 50Carcinoma, Renal Cell 49Colorectal Neoplasms 46Small Cell Lung Carcinoma 45Pancreatic Neoplasms 45Esophageal Neoplasms 45Neoplasms 43Uterine Cervical Neoplasms 41Breast Neoplasms 38Advanced or Metastatic Solid Tumors 35Hematopoietic and Lymphatic System Neoplasm 34Neoplasm Metastasis 33Squamous Cell Carcinoma of Head and Neck 32Advanced Malignant Solid Tumors 31Solid Tumours 30Triple Negative Breast Neoplasms 29

Interventions

1-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Platinum-resistant Recurrent Ovarian Cancer × Other solid neoplasm × Clear all
NCT06687070 2025-02-26

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Ascentage Pharma Group Inc.

Phase 1 Recruiting
50 enrolled
GynecologicOther solid neoplasm

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡